Based on the above findings that c-Myc inhibition can enhance T cell infiltration and activate the CD40/CD40L costimulatory pathway, we speculated that the combination of a c-Myc inhibitor and an anti-PD-1 antibody might have a synergistic therapeutic effect in osteosarcoma. The gene discussed is PDCD1; the disease is osteosarcoma.